cis p-tau: early driver of brain injury and tauopathy blocked by antibody

• Published in: Nature (London) 2015-07, Vol.523 (7561), p.431-436
• Main Authors: Kondo, Asami, Shahpasand, Koorosh, Mannix, Rebekah, Qiu, Jianhua, Moncaster, Juliet, Chen, Chun-Hau, Yao, Yandan, Lin, Yu-Min, Driver, Jane A, Sun, Yan, Wei, Shuo, Luo, Man-Li, Albayram, Onder, Huang, Pengyu, Rotenberg, Alexander, Ryo, Akihide, Goldstein, Lee E, Pascual-Leone, Alvaro, McKee, Ann C., Meehan, William, Zhou, Xiao Zhen, Lu, Kun Ping
• Format: Article
• Language: English
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/nature14658

Traumatic brain injury (TBI), characterized by acute neurological dysfunction, is one of the best known environmental risk factors for chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD), whose defining pathologic features include tauopathy made of phosphorylated tau (p-tau). However, tauopathy has not been detected in early stages after TBI and how TBI leads to tauopathy is unknown. Here we find robust cis p-tau pathology after sport- and military-related TBI in humans and mice. Acutely after TBI in mice and stress in vitro, neurons prominently produce cis p-tau, which disrupts axonal microtubule network and mitochondrial transport, spreads to other neurons, and leads to apoptosis. This process, termed “cistauosis”, appears long before other tauopathy. Treating TBI mice with cis antibody blocks cistauosis, prevents tauopathy development and spread, and restores many TBI-related structural and functional sequelae. Thus, cis p-tau is a major early driver after TBI and leads to tauopathy in CTE and AD, and cis antibody may be further developed to detect and treat TBI, and prevent progressive neurodegeneration after injury.